AbbVie Raises 2025 Outlook After Q2 Beat

AbbVie(NYSE:ABBV) reported second quarter 2025 results on July 31, 2025, delivering adjusted EPS of $2.97 (up $0.11 from guidance midpoint) and net revenues of $15.4 billion (up $400 million from expectations). Management raised full-year revenue guidance by $800 million, to $60.5 billion, and adjusted EPS (non-GAAP) guidance by $0.21 to a range of $11.88-$12.08, fueled by robust growth in immunology (SKYRIZI, RINVOQ) and neuroscience portfolios. The following insights detail pivotal drivers of performance, R&D pipeline expansion, and revenue diversification critical to AbbVie’s long-term thesis.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool